Science & Technology
Characterization of a novel non-hallucinogenic psilocybin derivative for alcohol use disorder
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R44AA031925-01
Award Ceiling
$320K
Award Floor
$320K
Close Date
Feb 28, 2026
Total Funding
$320K
Expected Awards
1
Posted Date
Sep 15, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R44AA031925-01
Description
SBIR Phase Phase I award: "Characterization of a novel non-hallucinogenic psilocybin derivative for alcohol use disorder" awarded to Psilera, Inc. in TAMPA, Florida. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $320,263. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Socially/economically disadvantaged, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.